secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001683168-24-006053
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 29 to maintain Nasdaq listing
--------------------------------------------------------------------------------

- Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.
- Post-split common shares outstanding ~1M; trading begins on split-adjusted basis Aug 30, 2024.
- Split intended to meet Nasdaq $1 minimum bid price requirement by Sept 16, 2024; no assurance of compliance.
- Stockholders re-elected Philippe Weigerstorfer and Amy Trombly as Class I directors; reincorporation to Nevada not approved.
- All proposals at annual meeting approved except reincorporation; auditor ratified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316824006053/0001683168-24-006053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316824006053/sonoma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-006053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer